Advice

following an abbreviated submission:

dolutegravir, abacavir plus lamivudine tablets (Triumeq®) are accepted for use within NHS Scotland.

Indication under review: for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.

In patients for whom this combination is appropriate, it offers a single tablet at a lower cost per dose compared with the individual components.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of (Triumeq®). This advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.

 

Download detailed advice72KB (PDF)

Download

Medicine details

Medicine name:
dolutegravir, abacavir, lamivudine (Triumeq)
SMC ID:
1009/14
Indication:
for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg.
Pharmaceutical company
ViiV Healthcare/GSK
BNF chapter
Infections
Submission type
Abbreviated
Status
Accepted
Date advice published
08 December 2014